Invitae Corporation logo
Invitae Corporation NVTA

Quarterly report 2023-Q3
added 11-08-2023

report update icon

Invitae Corporation Income Statement 2011-2026 | NVTA

Annual Income Statement Invitae Corporation

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

511 M 2.37 B 6.66 B 1.78 B 934 M 326 M 275 M 197 M - - - -

Shares

236 M 211 M 135 M 90.9 M 66.7 M 46.5 M 33.2 M 28.2 M - - - -

Historical Prices

2.17 11.2 49.5 18.6 14.1 6.89 8.37 7 - - - -

Net Income

-99.8 M -205 M -602 M -242 M -129 M -123 M -100 M -89.8 M -47.5 M -24.8 M -8.6 M -

Revenue

122 M 126 M 280 M 217 M 148 M 68.2 M 25 M 8.38 M 1.6 M 148 K - -

Cost of Revenue

92.8 M 96.1 M 198 M 118 M 80.1 M 50.1 M 27.9 M 16.5 M 5.62 M 667 K - -

Gross Profit

- - - 98.7 M 67.6 M 18.1 M -2.83 M -8.14 M -4.02 M -519 K - -

Operating Income

-94.9 M -215 M -652 M -244 M -123 M -121 M -100 M -89.5 M -47.4 M -24.8 M - -

Interest Expense

56.7 M 49.9 M 29.8 M 12.4 M 7.03 M 3.65 M 421 K 211 K 61 K 59 K - -

EBITDA

47.2 M -134 M -613 M -228 M -109 M -112 M -93.6 M -84.2 M -45 M -23.8 M -8.28 M -

Operating Expenses

- - - 343 M 190 M 139 M 97.4 M 81.3 M 43.3 M 24.2 M - -

General and Administrative Expenses

192 M 248 M 270 M 79.1 M 52.2 M 39.5 M 24.1 M 16 M 12.6 M 5.76 M 3 M -

All numbers in USD currency

Quarterly Income Statement Invitae Corporation

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

276 M 264 M 250 M - 238 M 232 M 228 M 228 M 218 M 204 M 194 M 186 M 132 M 129 M 99.6 M 98.8 M 95.6 M 90.9 M 79.4 M 75.5 M 70.2 M 67.8 M 54.4 M 53.6 M 48.2 M 43.2 M 42.3 M 41.1 M 32.3 M 32.2 M 32 M 31.9 M 31.9 M 31.8 M 17.1 M 945 K 886 K 823 K 749 K - - - - - - - - - - - -

Net Income

-942 M -207 M -192 M - -301 M -2.52 B -182 M -205 M -198 M 134 M -109 M -234 M -103 M -166 M -98.5 M -76.9 M -78.7 M -48.7 M -37.7 M -29.8 M -31.7 M -31.7 M -36.1 M -40.5 M -27.4 M -123 M -123 M -24.8 M -100 M -100 M -100 M -24.4 M -22.5 M -24.3 M -18.6 M -15.3 M -12.6 M -10.5 M -9.03 M - - - - - - - - - - - -

Revenue

121 M 121 M 117 M - 134 M 137 M 124 M 126 M 114 M 116 M 104 M 100 M 68.7 M 46.2 M 64.2 M 66.3 M 56.5 M 53.5 M 40.6 M 45.4 M 37.4 M 37.3 M 27.7 M 25.4 M 18.1 M 14.3 M 10.3 M 9.24 M 6.28 M 5.58 M 3.96 M 3.16 M 2.19 M 1.8 M 1.23 M 875 K 310 K 301 K 118 K - - - - - - - - - - - -

Cost of Revenue

82.2 M 87.5 M 88.4 M - 117 M 110 M 97.1 M 96.1 M 87.7 M 89.3 M 75.5 M 68.3 M 46.6 M 43 M 40.4 M 36.7 M 32.1 M 28 M 21.3 M 21.1 M 20.4 M 20.4 M 18.1 M 17 M 13.3 M 10.5 M 9.33 M - 7.24 M 6.48 M 5.99 M - 3.95 M 3.87 M 3.2 M - 1.69 M 963 K 611 K - - - - - - - - - - - -

Operating Income

-980 M -226 M -175 M - -290 M -2.52 B -213 M -215 M -193 M 129 M -112 M -331 M -80.8 M -142 M -97.8 M -79 M -77 M -51.9 M -36.2 M -25.9 M -30.1 M -30.1 M -36.5 M -34.9 M -31 M -28.1 M -27.3 M -25 M -24.9 M -24.8 M -25.5 M -24.3 M -22.5 M -24.1 M -18.6 M -15.3 M -12.5 M -10.5 M -9.02 M - - - - - - - - - - - -

Interest Expense

5.85 M 6.02 M 11.5 M - 14.1 M 14 M 14 M - 14.1 M 13.4 M 8.39 M - 6.31 M 5.48 M 5.45 M - 2.83 M 2.12 M 2.11 M - 1.84 M 1.79 M 1.29 M - 1.13 M 1.07 M 322 K - 115 K 100 K 84 K - 62 K 35 K 28 K - 15 K 17 K 17 K - - - - - - - - - - - -

EBITDA

-975 M -221 M -140 M - -280 M -2.51 B -186 M -215 M -136 M 164 M -95.8 M -331 M -57.9 M -128 M -91.7 M -79 M -65.8 M -45.2 M -32.9 M -25.9 M -19.8 M -23.1 M -33 M -34.9 M -25.1 M -24.6 M -25.6 M -25 M -20 M -21.6 M -23.9 M -24.3 M -18.7 M -21.8 M -17.6 M -15.3 M -11 M -9.55 M -8.55 M - - - - - - - - - - - -

General and Administrative Expenses

45.6 M 70 M 45.2 M - 44.9 M 50.9 M 51.4 M - 86.8 M 38.3 M 72.5 M - 27.8 M 26 M 23.8 M - 21.7 M 21.3 M 13.3 M - 13.7 M 12.4 M 11.8 M - 11.1 M 8.06 M 6.75 M - 5.66 M 6.38 M 5.76 M - 4.12 M 4.03 M 3.44 M - 3.21 M 3 M 1.9 M - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Invitae Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 -1.63 % $ 2.01 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 112.63 1.19 % $ 34.2 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 20.46 -1.63 % $ 1.09 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 14.99 1.28 % $ 453 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Castle Biosciences Castle Biosciences
CSTL
$ 24.5 1.07 % $ 681 M usaUSA
Illumina Illumina
ILMN
$ 124.54 3.46 % $ 19.8 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Charles River Laboratories International Charles River Laboratories International
CRL
$ 163.04 -0.45 % $ 8.08 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Guardant Health Guardant Health
GH
$ 84.06 0.78 % $ 10.5 B usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 17.07 5.11 % $ 180 M chinaChina
Lantheus Holdings Lantheus Holdings
LNTH
$ 80.71 -0.57 % $ 5.45 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 416.76 0.77 % $ 12 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.97 0.11 % $ 1.15 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 16.7 0.94 % $ 374 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.05 1.84 % $ 20 B niderlandNiderland
Personalis Personalis
PSNL
$ 5.1 1.19 % $ 302 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.37 -0.86 % $ 266 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.99 2.9 % $ 8.8 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Biomerica Biomerica
BMRA
$ 2.16 - $ 4.96 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 466.78 0.11 % $ 176 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 114.34 -1.58 % $ 9.43 B irlandaIrlanda
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.62 3.33 % $ 61.9 M irlandaIrlanda
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 256.62 -0.2 % $ 21.4 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 57.9 2.12 % $ 3.46 B usaUSA
Celcuity Celcuity
CELC
$ 117.65 -1.14 % $ 5.5 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Neogen Corporation Neogen Corporation
NEOG
$ 9.06 0.55 % $ 1.97 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.72 0.85 % $ 437 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Natera Natera
NTRA
$ 199.85 2.62 % $ 19.7 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 190.49 0.59 % $ 21.1 B usaUSA